Literature DB >> 7057567

Therapeutic use of albumin: 2.

M R Alexander, B Alexander, A L Mustion, R Spector, C B Wright.   

Abstract

It has previously been shown that albumin costs in a Veterans Administration Hospital constituted a large portion of the pharmacy drug budget and that much albumin was prescribed inappropriately. Therefore, a program of education and use monitoring was instituted to improve understanding and prescribing of this product. Inappropriate use declined from 41% to 26% of total albumin units and, more dramatically, total cost of albumin used had decreased by 90% one year after this program was initiated. Projected yearly savings from decreased use was more than $85,000. These results demonstrate that such a program can promote more appropriate use of albumin and effect a cost savings for hospitals.

Mesh:

Substances:

Year:  1982        PMID: 7057567

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Lowering the cost of lowering the cholesterol: a formulary policy for lovastatin.

Authors:  F A Lederle; E M Rogers
Journal:  J Gen Intern Med       Date:  1990 Nov-Dec       Impact factor: 5.128

2.  Effect of reactive pharmacy intervention on quality of hospital prescribing.

Authors:  C J Hawkey; S Hodgson; A Norman; T K Daneshmend; S T Garner
Journal:  BMJ       Date:  1990-04-14

3.  Production of recombinant albumin by a herd of cloned transgenic cattle.

Authors:  Yann Echelard; Jennifer L Williams; Margaret M Destrempes; Julie A Koster; Susan A Overton; Daniel P Pollock; Karen T Rapiejko; Esmail Behboodi; Nicholas C Masiello; William G Gavin; Jerry Pommer; Scott M Van Patten; David C Faber; Jose B Cibelli; Harry M Meade
Journal:  Transgenic Res       Date:  2008-11-22       Impact factor: 2.788

4.  Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA.

Authors:  Naghmeh Abiri; Jianlei Pang; Jiquan Ou; Bo Shi; Xianghong Wang; Sucai Zhang; Yunxia Sun; Daichang Yang
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.